



PTO/SB/08a/b (07-05)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet	1	of	1	Attorney Docket Number	A0345.0015
-------	---	----	---	------------------------	------------

Complete if Known

Application Number	10/554,702 - Conf. # 9370
Filing Date	October 27, 2005
First Named Inventor	Olivier Bezencon
Art Unit	1624
Examiner Name	K. Habte
Attorney Docket Number	A0345.0015

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
/KH/	BA	WO-97/09311	03-13-1997	Hoffmann La Roche		X
/KH/	BB	WO-03/093267	11-13-2003	Actelion Pharmaceuticals Ltd et al.		X
/KH/	BC	WO-04/002957	01-08-2004	Actelion Pharmaceuticals Ltd		X

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
/KH/	CA	Waeber B., et al., "THE RENIN-ANGIOTENSIN SYSTEM IN EXPERIMENTAL AND HUMAN HYPERTENSION", in Berkenhager W.H. Reid J.L. (eds): Handbook of Hypertension, Amsterdam, Elsevier Science Publishing Co., (1996), pp. 489-519	
	CB	Weber, M.A., Am. J. Hypertens., (1992), 5, 247S	
	CC	Rosenberg, M.E., et al., Kidney International, (1994), 45, 403	
	CD	Breyer, J.A., et al., Kidney International, (1994), 45, S156	
	CE	Vaughan, D.E., et al., Cardiovasc. Res., (1994), 28, 159	
	CF	Fouad-Tarazi, F., et al., Am. J. Med., (1988), 84 (Suppl. 3A), 83	
	CG	Pfeffer, M.A., et al., N. Engl. J. Med., (1992), 327, 669	
	CH	Kleinert, H.D., Cardiovasc. Drugs, (1995), 9, 645	
	CI	Husain, A., J. Hypertens., (1993), 11, 1155	
	CJ	Israili Z.H., et al., Annals of Internal Medicine, (1992), 117, 234	
	CK	Azizi M., et al., J. Hypertens., (1994) 12, 419	
	CL	Neutel, J.M., et al., Am. Heart, (1991), 122, 1094	
	CM	Rahuel, Jr., et al., Chem. Biol., (2000), 7, 493	
	CN	Mealy, N.E., Drugs of the Future, (2001) 26, 1139	
	CO	Oefner, C., et al., Chem. Biol., (1999), 6, 127	
	CP	Marki, H.P., et al., Il Farmaco, (2001), 56, 21	
	CQ	Majewski, M., et al., J. Org. Chem., (1995) 60, 5825	
	CR	Kiesewetter, D.O., Tetrahedron Asymmetry, (1993) 4, 2183	
	CS	Chen, Zhengming., Synthesis and Dopamine Transporter, J. Med. Chem., (1996), 39, 4744-4749	

Examiner Signature	/Kahsay Habte/	Date Considered	11/14/2007
--------------------	----------------	-----------------	------------